Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data

Background: Metastatic colorectal cancer (mCRC) represents a substantial health burden globally and an increasing challenge in Asian countries. Treatment options include chemotherapy plus a vascular endothelial growth factor (VEGF) inhibitor (such as bevacizumab, aflibercept or ramucirumab), or anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Muro, Kei, Salinardi, Taylor, Singh, Arvind Rup, Macarulla, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225956/
https://www.ncbi.nlm.nih.gov/pubmed/32244546
http://dx.doi.org/10.3390/cancers12040844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225956/
https://www.ncbi.nlm.nih.gov/pubmed/32244546
http://dx.doi.org/10.3390/cancers12040844

Ejemplares similares